Physician profile
John M Vasil
NPI 1629089982
$8,589.11
in general payments reported to CMS, 2019-2025
39 companies · $945 in 2025
The $945 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $1,043 · 2021: $1,497 · 2022: $1,641 · 2023: $1,364 · 2024: $1,340 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,611 · Education: $37.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,611.33 |
| Education | $37.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,728.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,260.79 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $725.58 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Amarin Pharma, INC. | $554.12 | 2019-2023 | |
| Glaxosmithkline, LLC. | $464.41 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.72 | 2019-2025 | Jardiance, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $319.77 | 2019-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $276.81 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Kowa Pharmaceuticals America, INC. | $269.86 | 2022-2023 | Seglentis, Livalo |
| Indivior INC. | $258.94 | 2019-2025 | Sublocade |
| Orexo US, INC. | $255.65 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $247.67 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $211.63 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $209.47 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $199.13 | 2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $179.33 | 2023-2025 | Brixadi |
| Paratek Pharmaceuticals, INC. | $164.75 | 2024-2025 | Nuzyra |
| Lilly USA, LLC | $160.77 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $96.04 | 2020-2025 | Repatha |
| Sanofi Pasteur INC. | $80.95 | 2020-2023 | |
| Shield Therapeutics INC | $72.85 | 2023-2024 | Accrufer |
| Phathom Pharmaceuticals, INC. | $66.24 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $49.74 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.56 | 2025 | Caplyta |
| Abbott Laboratories | $44.12 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $30.27 | 2019-2020 | |
| Boston Scientific Corporation | $29.79 | 2020-2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $29.52 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.09 | 2024 | Lifevest |
| Astellas Pharma US INC | $22.93 | 2025 | Veozah |
| Allergan, INC. | $22.87 | 2020 | |
| Idorsia Pharmaceuticals US INC | $19.26 | 2022 | |
| Inspire Medical Systems, INC. | $18.27 | 2024 | Inspire |
| Medtronic, INC. | $18.14 | 2023 | Intellis Adaptivestim |
| Regeneron Healthcare Solutions, INC. | $16.91 | 2021 | |
| Sumitomo Pharma America, INC. | $15.73 | 2024 | Gemtesa |
| Dexcom, INC. | $15.66 | 2024 | Dexcom G6 Transmitter |
| Athena Bioscience, LLC | $14.86 | 2024 | Nexiclon Xr |
| Nabriva Therapeutics, Plc | $12.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vasil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.